Luxembourg has a young and ambitious life sciences community, which has identified four aspects of personalized medicine where the country has significant potential: digital health, neurodegenerative diseases, molecular diagnostics and immune-oncology. Thomas Dentzer, Head of the Life Sciences sector in Luxembourg, discusses the flexible and supportive atmosphere for companies and researchers in Luxembourg.
The Luxembourg BioHealth cluster was created in 2008, joining the league of many other hubs, science parks, and cluster organizations at the European level. In what can be considered a very competitive environment, what sets Luxembourg’s BioHealth cluster apart from other such clusters across Europe?
"What sets us apart as a cluster ... is the inclusiveness of our community – we don’t just count companies or research institutions among our members, but also government policy makers and funding agencies."
